5
Parmax Pharma
PARMAXPHARMALTD NSE
Parmax Pharma
HealthcareNSE: PARMAXPHARMALTD BSE: 540359 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹91.10 Cr
P/E Ratio
-76.1
EBITDA
₹-3.64 Cr
Return on Equity
105.3%
Debt to Equity
0
Book Value
₹6.68
52W High
₹132.45
52W Low
₹22.6
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is expected to give good quarter
- Promoter holding has increased by 33.9% over last quarter.
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -14.3% over past five years.
- Debtor days have increased from 57.4 to 95.2 days.
Growth Rate
Revenue Growth
-57.06% lower than
3Y
Net Income Growth
179% higher than
3Y
Cash Flow Change
-380% higher than
3Y
ROE
-102%
ROCE
-61.52% higher than
3Y
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.4 | 4.07 | 1.33 | 4.26 | 7.82 | 9.28 | 6.28 | 4.83 | 1.94 | 2.53 | 4.33 | 3.31 | 8.22 |
| Expenses | 2.05 | 4.84 | 2.48 | 5.06 | 7.31 | 9.08 | 6.17 | 5.39 | 2.19 | 4.12 | 4.53 | 4.86 | 7.39 |
| Operating Profit | -0.65 | -0.77 | -1.15 | -0.8 | 0.51 | 0.2 | 0.11 | -0.56 | -0.25 | -1.59 | -0.2 | -1.55 | 0.83 |
| OPM % | -46.43% | -18.92% | -86.47% | -18.78% | 6.52% | 2.16% | 1.75% | -11.59% | -12.89% | -62.85% | -4.62% | -46.83% | 10.1% |
| Other Income | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.12 | 0.01 | -1.17 | 0.01 | 0.01 | 0.01 | 0.03 | 2.08 |
| Interest | 0.12 | 0.18 | 0.16 | 0.16 | 0.11 | 0.13 | 0.11 | 0.24 | 0.28 | 0.24 | 0.28 | 0.5 | 0.23 |
| Depreciation | 0.42 | 0.43 | 0.45 | 0.41 | 0.4 | 0.4 | 0.41 | -0.18 | 0.24 | 0.26 | 0.27 | 0.25 | 0.48 |
| PBT | -1.18 | -1.37 | -1.75 | -1.36 | 0.01 | -0.21 | -0.4 | -1.79 | -0.76 | -2.08 | -0.74 | -2.27 | 2.2 |
| Tax % | 0% | 0% | 0% | 6.62% | 0% | 0% | 0% | -16.76% | 0% | 0% | 0% | -74.45% | 0% |
| Net Profit | -1.18 | -1.37 | -1.75 | -1.45 | 0.01 | -0.22 | -0.39 | -1.49 | -0.76 | -2.08 | -0.73 | -0.58 | 2.2 |
| EPS in Rs | -3.15 | -3.66 | -4.68 | -3.88 | 0.03 | -0.59 | -1.04 | -3.98 | -2.03 | -5.56 | -1.95 | -1.55 | 5.88 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.39 | 11.02 | 28.2 | 12.11 | 18.39 |
| Expenses | 0.02 | 0.05 | 0.05 | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.14 | 14.39 | 27.94 | 15.75 | 20.9 |
| Operating Profit | -0.02 | -0.05 | -0.05 | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.25 | -3.37 | 0.26 | -3.64 | -2.51 |
| OPM % | — | — | — | 9.08% | 9.26% | 8.46% | 13.11% | 14.09% | 14.62% | -30.58% | 0.92% | -30.06% | -13.65% |
| Other Income | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.1 | 0.09 | 0.06 | 0.04 | 0.05 | -1.03 | 0.05 | 2.13 |
| Interest | 0 | 0 | 0 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.37 | 0.62 | 0.59 | 1.24 | 1.25 |
| Depreciation | 0 | 0 | 0 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.03 | 1.01 | 1.26 |
| PBT | 0.04 | 0.01 | 0.01 | 0 | 0.1 | 0.73 | 1.21 | 0.31 | 0.04 | -5.65 | -2.39 | -5.84 | -2.89 |
| Tax % | 25% | 200% | 100% | — | 20% | 41.1% | 38.02% | 54.84% | 375% | 1.77% | -12.55% | -28.94% | — |
| Net Profit | 0.02 | 0 | -0.01 | 0 | 0.08 | 0.43 | 0.75 | 0.14 | -0.1 | -5.75 | -2.09 | -4.16 | -1.19 |
| EPS in Rs | 0.05 | 0 | -0.03 | 0 | 0.21 | 1.15 | 2 | 0.37 | -0.27 | -15.37 | -5.59 | -11.12 | -3.18 |
| Div. Payout % | 0% | — | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.03 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
| Reserves | 0.12 | 0.11 | 0.1 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.4 | -4.35 | -6.44 | -10.6 |
| Borrowings | 0.79 | 0.46 | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.91 | 7.71 | 11.52 |
| Other Liabilities | 0.04 | 0.06 | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 9.32 | 13.03 | 22.68 |
| Total Liabilities | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 28.05 |
| Fixed Assets | 2.53 | 2.53 | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.5 | 9.27 | 7.97 | 7.86 |
| CWIP | 0 | 0 | 0 | 0 | 3.33 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0.2 | 0.2 | 0.2 | 0 | 0 | 0 | 0.4 | 0.4 |
| Other Assets | 2.45 | 2.55 | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 5.96 | 10.38 | 19.79 |
| Total Assets | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 28.05 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.06 | 0 | -0.5 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | -0.2 | -0.96 | -2.36 |
| Investing | 0 | 0 | -0.19 | -4.23 | -3.41 | -2.4 | -3.15 | -1.53 | -0.94 | -1.59 | -0.7 | -0.9 |
| Financing | 0 | 0.1 | 0.56 | 1.14 | 3.1 | -0.23 | 0.4 | -0.91 | -0.04 | 1.43 | 1.4 | 3.81 |
| Net Cash Flow | -0.06 | 0.09 | -0.14 | 0.79 | 0.61 | 0.2 | 0.78 | -1.69 | -0.65 | -0.36 | -0.26 | 0.56 |
| Free Cash Flow | -0.06 | 0 | -0.69 | -0.35 | -2.49 | 0.42 | 0.38 | -0.78 | -0.61 | -1.79 | -1.66 | -3.26 |
| CFO/OP | 300 | 0 | 1,000 | 359 | 83 | 159 | 103 | 29 | 15 | 6 | -369 | 65 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | — | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.7 | 60.28 | 16.57 | 95.24 |
| Inventory Days | — | — | — | 203 | 279 | 88.17 | 107 | 155 | 287 | 124 | 56.09 | 290 |
| Days Payable | — | — | — | 609 | 645 | 312 | 269 | 300 | 310 | 383 | 173 | 530 |
| Cash Conversion Cycle | — | — | — | -346 | -331 | -166 | -139 | -131 | -8.57 | -199 | -101 | -145 |
| Working Capital Days | — | — | — | -59.86 | -71.84 | -56.18 | -48.26 | -36.02 | -0.47 | -116 | -40.38 | -200 |
| ROCE % | 0.81% | 0.2% | 0.19% | 0.66% | 1.56% | 8.4% | 14.34% | 6.13% | 3.67% | -58.39% | -12.45% | -82.96% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Parmax Pharma insights
60 extracted metrics + investor summaries across FY13–FY26.
Documents
3
Announcement under Regulation 30 (LODR)-Change in Management
2 May - Board reappointed Dr. Umang Gosalia as Managing Director for five years from June 28, 2026. 2 May - Board reappointed Dr. Umang Gosalia as Managing Director for five years from June 28, 2026.
4
Announcement under Regulation 30 (LODR)-Change in Management
2 May - Board reappointed Dr. Umang Gosalia as Managing Director for five years from June 28, 2026. 2 May - Board reappointed Dr. Umang Gosalia as Managing Director for five years from June 28, 2026.
5
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Parmax Pharma confirms it is not a Large Corporate under SEBI circulars. 30 Apr - Parmax Pharma confirms it is not a Large Corporate under SEBI circulars.
Frequently Asked Questions about Parmax Pharma
What does Parmax Pharma Ltd do?
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.[1]
Where is Parmax Pharma Ltd (540359) listed?
Parmax Pharma Ltd trades as PARMAXPHARMALTD on the NSE and under code 540359 on the BSE.
Which sector does Parmax Pharma Ltd belong to?
Parmax Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Parmax Pharma Ltd?
Parmax Pharma Ltd has a market capitalisation of ₹91.1 Cr, which places it in the Small Cap band.
What is the PE ratio of Parmax Pharma Ltd?
Parmax Pharma Ltd trades at a PE ratio of -76.10, against a book value of ₹6.68 per share.
What is the 52-week high and low of Parmax Pharma Ltd?
Over the last 52 weeks Parmax Pharma Ltd has traded between ₹22.6 and ₹132.45.
What is the Return on Equity (ROE) of Parmax Pharma Ltd?
Parmax Pharma Ltd reported a return on equity of 105.30%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540359.md for Parmax Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.